D H McKenna

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN University of Minnesota School of Medicine, Minneapolis, MN 55407, USA
    Am Heart J 158:356-63. 2009
  2. doi request reprint Clinical production and therapeutic applications of alloreactive natural killer cells
    David H McKenna
    Department of Laboratory Medicine and Pathology, Cancer Centre and Molecular and Cellular Therapeutics, University of Minnesota, Minneapolis, MN, USA
    Methods Mol Biol 882:491-507. 2012
  3. doi request reprint Umbilical cord blood: current status and future directions
    D H McKenna
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota, Saint Paul, MN 55108, USA
    Vox Sang 100:150-62. 2011
  4. pmc CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine
    David H McKenna
    University of Minnesota, Minneapolis, Minnesota 55108, USA
    Cytotherapy 12:170-7. 2010
  5. ncbi request reprint HLA alloimmunization in patients requiring ventricular assist device support
    David H McKenna
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Heart Lung Transplant 21:1218-24. 2002
  6. ncbi request reprint Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience
    David H McKenna
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School, Minnesota 55108, USA
    Transfusion 47:520-8. 2007
  7. ncbi request reprint The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory
    David H McKenna
    Division of Minnesota Molecular and Cellular Therapeutics Facility, University of Minnesota, Saint Paul, MN 55108, USA
    Transfus Med Rev 19:217-28. 2005
  8. pmc Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units
    Michael R Verneris
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 114:4293-9. 2009
  9. pmc Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Blood 117:1061-70. 2011
  10. pmc Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute, Abbott Northwestern Hospital, MN 55407, USA
    Am Heart J 160:428-34. 2010

Detail Information

Publications16

  1. pmc Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, Minneapolis, MN University of Minnesota School of Medicine, Minneapolis, MN 55407, USA
    Am Heart J 158:356-63. 2009
    ..This study will provide further insight into the clinical feasibility and appropriate timing of autologous BMMNC therapy in high-risk patients after AMI and percutaneous coronary intervention...
  2. doi request reprint Clinical production and therapeutic applications of alloreactive natural killer cells
    David H McKenna
    Department of Laboratory Medicine and Pathology, Cancer Centre and Molecular and Cellular Therapeutics, University of Minnesota, Minneapolis, MN, USA
    Methods Mol Biol 882:491-507. 2012
    ....
  3. doi request reprint Umbilical cord blood: current status and future directions
    D H McKenna
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota, Saint Paul, MN 55108, USA
    Vox Sang 100:150-62. 2011
    ..Novel approaches to UCB transplantation include use of two units and a variety of graft manipulations. Additional uses for UCB are currently being explored and include applications in regenerative medicine and immunotherapy...
  4. pmc CD34(+) cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine
    David H McKenna
    University of Minnesota, Minneapolis, Minnesota 55108, USA
    Cytotherapy 12:170-7. 2010
    ..The impact on CD34(+) recovery using a full versus half vial of Isolex(R) CD34 reagent and the effects of shipping a post-selection product were evaluated...
  5. ncbi request reprint HLA alloimmunization in patients requiring ventricular assist device support
    David H McKenna
    Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    J Heart Lung Transplant 21:1218-24. 2002
    ..We looked at HLA antibody formation in our patients during VAD support to determine the rate and potential causes of antibody formation...
  6. ncbi request reprint Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience
    David H McKenna
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota Medical School, Minnesota 55108, USA
    Transfusion 47:520-8. 2007
    ..Herein is a report on the experience of clinical-scale, good manufacturing practices (GMPs) production of NK cells to treat advanced cancer...
  7. ncbi request reprint The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory
    David H McKenna
    Division of Minnesota Molecular and Cellular Therapeutics Facility, University of Minnesota, Saint Paul, MN 55108, USA
    Transfus Med Rev 19:217-28. 2005
    ..Here we provide an overview of the Minnesota Molecular and Cellular Therapeutics (MMCT) Facility, detailing our approach to the manufacture of novel therapeutics and highlighting current and future activities...
  8. pmc Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units
    Michael R Verneris
    Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Blood 114:4293-9. 2009
    ..This trial was registered at http://clinicaltrials.gov as NCT00309842...
  9. pmc Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
    Claudio G Brunstein
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Blood 117:1061-70. 2011
    ..These results set the stage for a definitive study of UCB Treg to determine its potency in preventing allogeneic aGVHD. This study is registered at http://www.clinicaltrials.gov as NCT00602693...
  10. pmc Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction
    Jay H Traverse
    Minneapolis Heart Institute, Abbott Northwestern Hospital, MN 55407, USA
    Am Heart J 160:428-34. 2010
    ..However, results from trials performed in the United States have not yet been presented...
  11. doi request reprint Allogeneic natural killer cells for refractory lymphoma
    Veronika Bachanova
    Blood and Marrow, Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Immunol Immunother 59:1739-44. 2010
    ..Cell therapy trials should incorporate novel strategies to limit Treg expansion...
  12. ncbi request reprint Cell loss and recovery in umbilical cord blood processing: a comparison of postthaw and postwash samples
    Vincent Laroche
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Transfusion 45:1909-16. 2005
    ..This study examines the effect of the wash step as well as that of PT storage on various quality control variables of UCB units...
  13. ncbi request reprint Microbial contamination of hematopoietic stem cell products: incidence and clinical sequelae
    Mark A Klein
    Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 12:1142-9. 2006
    ..Prophylactic antibiotics are useful for certain contaminants; however, caution must be exercised when gram-negative contaminated products are administered...
  14. pmc Factors predicting single-unit predominance after double umbilical cord blood transplantation
    P Ramirez
    Department of Medicine, University of Minnesota, Blood and Marrow Transplant Program, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 47:799-803. 2012
    ..4; P=0.05) were independent factors associated with unit predominance. Taken together, these findings suggest that immune reactivity has a role in unit predominance, and should be considered during graft selection and graft manipulation...
  15. doi request reprint Loss of integrity of umbilical cord blood unit freezing bags: description and consequences
    Bharat Thyagarajan
    Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, University of Minnesota, Minneapolis, MN 55108, USA
    Transfusion 48:1138-42. 2008
    ..Because UCB units are selected on an individual basis to maximize the chance of engraftment, loss of container integrity may have adverse effects on patient outcome...
  16. ncbi request reprint Viability does not necessarily reflect the hematopoietic progenitor cell potency of a cord blood unit: results of an interlaboratory exercise
    Anneke Brand
    Leiden Cord Bloodbank, Sanquin, The Netherlands
    Transfusion 48:546-9. 2008
    ..Another reason for a discrepancy between the number of cells in the unit released by the cord blood bank and found in the transplant center may be technical differences in cell counting methods between the two sites...